BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

BACKGROUND: Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing a major adverse cardiac event. Dysregulation of epigenetic mechanisms of gene transcription in innate immune cells contributes to CVD development but is currently not targeted...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Epigenetics
Autors principals: Wasiak, Sylwia, Dzobo, Kim E., Rakai, Brooke D., Kaiser, Yannick, Versloot, Miranda, Bahjat, Mahnoush, Stotz, Stephanie C., Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Stroes, Erik S. G., Kroon, Jeffrey, Kulikowski, Ewelina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657365/
https://ncbi.nlm.nih.gov/pubmed/33172487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-020-00943-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars